Summary
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
SLNO shares surge as Neurocrine inks $2.9B cash deal to acquire it at $53 a share, adding Vykat XR and expanding its rare disease and endocrinology portfolio.
Soleno Therapeutics, Inc. $SLNO Holdings Lifted by Avoro Capital Advisors LLC
Avoro Capital Advisors LLC boosted its holdings in shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO) by 25.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,577,777 shares of the company's stock after acquiring an additional 527,777 shares during the quarter. Soleno Therapeutics
Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call Transcript
Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call Transcript
Soleno Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 29 | $2,429.81 | $1,537.29 | -$892.52 | -36.73% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 74 | $2,477.52 | $3,922.74 | $1,445.22 | 58.33% |
| BG Bart Gancher Intech Investment Management LLC | 14,109 | $1.18M | $747,918.09 | -$434,133.93 | -36.73% |
| NM Nir Messafi Deep Track Capita LLP | 1.08M | $48.94M | $57.18M | $8.25M | 16.85% |
 Joseph Castro Nuveen LLC | 104,738 | $8.34M | $5.55M | -$2.79M | -33.45% |
Soleno Therapeutics, Inc. (SLNO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Soleno Therapeutics, Inc. ever had a stock split?
Soleno Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Anish Bhatnagar CEO | NASDAQ (CM) Exchange | 834203309 CUSIP |
| US Country | 115 Employees | 6 Oct 2017 Last Dividend | 26 Aug 2022 Last Split | 13 Nov 2014 IPO Date |
Overview
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics for the treatment of rare diseases. Originally founded in 1999 as Capnia, Inc., the company underwent a name change to Soleno Therapeutics, Inc. in May 2017, marking a new chapter in its journey. With its headquarters in Redwood City, California, Soleno Therapeutics is at the forefront of addressing unmet medical needs through its robust pipeline of novel treatments.
Products and Services
- Diazoxide Choline Extended-Release (DCE) Tablets
This flagship product of Soleno Therapeutics represents a significant advancement in the treatment of Prader-Willi Syndrome (PWS), a rare genetic condition. The lead candidate, a once-daily oral tablet, is currently in Phase III clinical trials, showcasing the company's commitment to providing life-changing solutions for those affected by rare diseases. DCE tablets aim to improve the quality of life for patients with PWS by offering a novel therapeutic approach.
